Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?
Authors:
- 1 February 2012
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 30 (4) , 441-444
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian CancerJournal of Clinical Oncology, 2012
- Targeting the ANGPT–TIE2 pathway in malignancyNature Reviews Cancer, 2010
- Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapiesTrends in Pharmacological Sciences, 2009
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic TherapyClinical Cancer Research, 2009
- Angiopoietins in malignancyEuropean Journal of Surgical Oncology, 2007
- Angiopoietin-1 and Angiopoietin-2 Share the Same Binding Domains in the Tie-2 Receptor Involving the First Ig-like Loop and the Epidermal Growth Factor-like RepeatsJournal of Biological Chemistry, 2003
- Angiopoietin-2 Is Required for Postnatal Angiogenesis and Lymphatic Patterning, and Only the Latter Role Is Rescued by Angiopoietin-1Developmental Cell, 2002
- Vascular-specific growth factors and blood vessel formationNature, 2000
- Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1Science, 1999
- Increased Vascularization in Mice Overexpressing Angiopoietin-1Science, 1998